Rangsorolás az egészségügyben; gyógyszer-támogatási prioritások Magyarországon 2004-ben

Translated title of the contribution: Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004

Krisztián Kárpáti, Ágnes Brandtmüller, István Májer, L. Gulácsi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In our research we assessed the drug reimbursement of the National Health Insurance Fund Administration (NHIFA) in different ATC groups. We used the aggregated data of retail pharmacies in 2004, analysing separately the accentuated and elevated categories associated with medical indications. According to the 2004 data it was the drugs for cardiovascular, endocrine and metabolic disorders affecting the largest population and making the highest proportion of the total reimbursement. In addition, the turnover of some drugs for mental disorders was also significant. As for the number of patients in the cancer group it is much smaller, but as a result of the huge costs of their therapies these belong to the highest reimbursed categories as well. Without the special, separately financed category the annual drug subsidy was 257 bill. HUF, which totalled 423 bill. HUF on consumer price. The reimbursement of the NHIFA in the top 25 categories exceeded 177 bill. HUF. In the accentuated category the contribution of the NHIFA approximated 49 bill. HUF spent on the treatment of cancer, diabetic and some psychiatric disorders. In the elevated category based on health status the products of mental, digestive, bone and respiratory systems disorders were responsible for the highest turnover with more than 55 bill HUF subsidy. Besides knowing the amount of reimbursement it is also important to be familiar with the size of affected, treated population. However in many cases we do not have any detailed, up-to-date Hungarian data, so the under-, or the possible over-treatment can hardly be analysed accurately.

Original languageHungarian
Pages (from-to)191-199
Number of pages9
JournalActa Pharmaceutica Hungarica
Volume76
Issue number4
Publication statusPublished - 2006

Fingerprint

Hungary
National Health Programs
Delivery of Health Care
Pharmaceutical Preparations
Cardiovascular Agents
Digestive System
Pharmacies
Mental Disorders
Respiratory System
Population
Health Status
Psychiatry
Neoplasms
Therapeutics
Costs and Cost Analysis
Bone and Bones
Research

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Rangsorolás az egészségügyben; gyógyszer-támogatási prioritások Magyarországon 2004-ben. / Kárpáti, Krisztián; Brandtmüller, Ágnes; Májer, István; Gulácsi, L.

In: Acta Pharmaceutica Hungarica, Vol. 76, No. 4, 2006, p. 191-199.

Research output: Contribution to journalArticle

Kárpáti, Krisztián ; Brandtmüller, Ágnes ; Májer, István ; Gulácsi, L. / Rangsorolás az egészségügyben; gyógyszer-támogatási prioritások Magyarországon 2004-ben. In: Acta Pharmaceutica Hungarica. 2006 ; Vol. 76, No. 4. pp. 191-199.
@article{19fe1465335c4c23829651d1485b7a6b,
title = "Rangsorol{\'a}s az eg{\'e}szs{\'e}g{\"u}gyben; gy{\'o}gyszer-t{\'a}mogat{\'a}si priorit{\'a}sok Magyarorsz{\'a}gon 2004-ben",
abstract = "In our research we assessed the drug reimbursement of the National Health Insurance Fund Administration (NHIFA) in different ATC groups. We used the aggregated data of retail pharmacies in 2004, analysing separately the accentuated and elevated categories associated with medical indications. According to the 2004 data it was the drugs for cardiovascular, endocrine and metabolic disorders affecting the largest population and making the highest proportion of the total reimbursement. In addition, the turnover of some drugs for mental disorders was also significant. As for the number of patients in the cancer group it is much smaller, but as a result of the huge costs of their therapies these belong to the highest reimbursed categories as well. Without the special, separately financed category the annual drug subsidy was 257 bill. HUF, which totalled 423 bill. HUF on consumer price. The reimbursement of the NHIFA in the top 25 categories exceeded 177 bill. HUF. In the accentuated category the contribution of the NHIFA approximated 49 bill. HUF spent on the treatment of cancer, diabetic and some psychiatric disorders. In the elevated category based on health status the products of mental, digestive, bone and respiratory systems disorders were responsible for the highest turnover with more than 55 bill HUF subsidy. Besides knowing the amount of reimbursement it is also important to be familiar with the size of affected, treated population. However in many cases we do not have any detailed, up-to-date Hungarian data, so the under-, or the possible over-treatment can hardly be analysed accurately.",
author = "Kriszti{\'a}n K{\'a}rp{\'a}ti and {\'A}gnes Brandtm{\"u}ller and Istv{\'a}n M{\'a}jer and L. Gul{\'a}csi",
year = "2006",
language = "Hungarian",
volume = "76",
pages = "191--199",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "4",

}

TY - JOUR

T1 - Rangsorolás az egészségügyben; gyógyszer-támogatási prioritások Magyarországon 2004-ben

AU - Kárpáti, Krisztián

AU - Brandtmüller, Ágnes

AU - Májer, István

AU - Gulácsi, L.

PY - 2006

Y1 - 2006

N2 - In our research we assessed the drug reimbursement of the National Health Insurance Fund Administration (NHIFA) in different ATC groups. We used the aggregated data of retail pharmacies in 2004, analysing separately the accentuated and elevated categories associated with medical indications. According to the 2004 data it was the drugs for cardiovascular, endocrine and metabolic disorders affecting the largest population and making the highest proportion of the total reimbursement. In addition, the turnover of some drugs for mental disorders was also significant. As for the number of patients in the cancer group it is much smaller, but as a result of the huge costs of their therapies these belong to the highest reimbursed categories as well. Without the special, separately financed category the annual drug subsidy was 257 bill. HUF, which totalled 423 bill. HUF on consumer price. The reimbursement of the NHIFA in the top 25 categories exceeded 177 bill. HUF. In the accentuated category the contribution of the NHIFA approximated 49 bill. HUF spent on the treatment of cancer, diabetic and some psychiatric disorders. In the elevated category based on health status the products of mental, digestive, bone and respiratory systems disorders were responsible for the highest turnover with more than 55 bill HUF subsidy. Besides knowing the amount of reimbursement it is also important to be familiar with the size of affected, treated population. However in many cases we do not have any detailed, up-to-date Hungarian data, so the under-, or the possible over-treatment can hardly be analysed accurately.

AB - In our research we assessed the drug reimbursement of the National Health Insurance Fund Administration (NHIFA) in different ATC groups. We used the aggregated data of retail pharmacies in 2004, analysing separately the accentuated and elevated categories associated with medical indications. According to the 2004 data it was the drugs for cardiovascular, endocrine and metabolic disorders affecting the largest population and making the highest proportion of the total reimbursement. In addition, the turnover of some drugs for mental disorders was also significant. As for the number of patients in the cancer group it is much smaller, but as a result of the huge costs of their therapies these belong to the highest reimbursed categories as well. Without the special, separately financed category the annual drug subsidy was 257 bill. HUF, which totalled 423 bill. HUF on consumer price. The reimbursement of the NHIFA in the top 25 categories exceeded 177 bill. HUF. In the accentuated category the contribution of the NHIFA approximated 49 bill. HUF spent on the treatment of cancer, diabetic and some psychiatric disorders. In the elevated category based on health status the products of mental, digestive, bone and respiratory systems disorders were responsible for the highest turnover with more than 55 bill HUF subsidy. Besides knowing the amount of reimbursement it is also important to be familiar with the size of affected, treated population. However in many cases we do not have any detailed, up-to-date Hungarian data, so the under-, or the possible over-treatment can hardly be analysed accurately.

UR - http://www.scopus.com/inward/record.url?scp=33846411433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846411433&partnerID=8YFLogxK

M3 - Article

C2 - 17575799

AN - SCOPUS:33846411433

VL - 76

SP - 191

EP - 199

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 4

ER -